Valuation: Novartis

Market Cap 30TCr 26TCr 24TCr 22TCr 42TCr 28,51200Cr 42TCr 2,86800Cr 1,12000Cr 13,97600Cr 1,10800Cr 1,08500Cr 48,36700Cr P/E 2026 *
21.6x
P/E 2027 * 18.6x
Enterprise Value 33TCr 29TCr 27TCr 25TCr 46TCr 31,70900Cr 47TCr 3,18900Cr 1,24500Cr 15,54300Cr 1,23300Cr 1,20600Cr 53,79100Cr EV / Sales 2026 *
5.71x
EV / Sales 2027 * 5.3x
Free-Float
91.66%
Yield 2026 *
2.81%
Yield 2027 * 2.94%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+2.30%+49.71%+158.86% 1,05700Cr
+1.59%+5.37%+55.77%+54.77% 62TCr
+0.95%+1.95%+36.11%+80.44% 45TCr
+1.60%+7.09%+35.90%+29.32% 34TCr
-0.14%+0.33%+18.70%+17.64% 26TCr
+0.09%-4.53%-27.60%-42.19% 22TCr
+1.22%+1.20%+21.61%+60.14% 20TCr
-1.18%-5.13%+13.87%+60.35% 16TCr
-0.16%-2.39%-3.23%-34.39% 14TCr
Average +0.24%+0.32%+22.31%+42.77% 38.44TCr
Weighted average by Cap. +0.09%+1.31%+35.00%+75.49%

Financials

2026 *2027 *
Net sales 5.75TCr 5.06TCr 4.7TCr 4.32TCr 8.1TCr 5,55300Cr 8.24TCr 56TCr 22TCr 2,72200Cr 22TCr 21TCr 9,42000Cr 6.1TCr 5.37TCr 4.99TCr 4.58TCr 8.59TCr 5,88900Cr 8.74TCr 59TCr 23TCr 2,88700Cr 23TCr 22TCr 9,99000Cr
Net income 1.4TCr 1.23TCr 1.14TCr 1.05TCr 1.97TCr 1,34900Cr 2TCr 14TCr 5.3TCr 66TCr 5.24TCr 5.13TCr 2,28800Cr 1.56TCr 1.38TCr 1.28TCr 1.17TCr 2.2TCr 1,51000Cr 2.24TCr 15TCr 5.93TCr 74TCr 5.87TCr 5.74TCr 2,56100Cr
Net Debt 3.31TCr 2.91TCr 2.71TCr 2.49TCr 4.67TCr 3,19700Cr 4.74TCr 32TCr 13TCr 1,56700Cr 12TCr 12TCr 5,42400Cr 2.78TCr 2.45TCr 2.27TCr 2.09TCr 3.92TCr 2,68600Cr 3.99TCr 27TCr 11TCr 1,31700Cr 10TCr 10TCr 4,55600Cr
Logo Novartis
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA